BMO, Innergex at 52-Week Highs on News
Bank of Montreal (T.BMO) hit a new 52-week high of $149.19 Tuesday. BMO reported Non-GAAP EPS of C$3.04 beats by C$0.64, revenue of C$9.27B beats by C$680M. Innergex Renewable Energy Inc. (T.INE) hit a new 52-week high of $13.41 Tuesday. Innergex announced today it and CDPQ entered into a definitive agreement dated as of February 24, pursuant to which CDPQ will acquire all of the issued and outstanding common shares of Innergex for a price of $13.75 per share in cash. CI Financial Corp. (T.CIX) hit a new 52-week high of $31.37 Tuesday. No news stories today.Medical Facilities Corporation (T.DR) hit a new 52-week high of $17.46 Tuesday. No news stories today.Spectral Medical Inc. (T.EDT) hit a new 52-week high of 77 cents Tuesday. No news stories today.Extendicare Inc. (T.EXE) hit a new 52-week high of $11.53 Tuesday. No news stories today.The Fresh Factory B.C. Ltd. (V.FRSH) hit a new 52-week high of $1.10 Tuesday. No news stories today.Great-West Lifeco Inc. (T.GWO) hit a new 52-week high of $52.74 Tuesday. No news stories today.International Petroleum Corporation (T.IPCO) hit a new 52-week high of $21.02 Tuesday. No news stories today.Metro Inc. (T.MRU) hit a new 52-week high of $96.54 Tuesday. No news stories today.Power Corporation of Canada (T.POW) hit a new 52-week high of $47.81 Tuesday. No news stories today.
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


